Remarkably, the loss of specific tumor suppressor genes in GBM identifies common subsets of patients (e.g. CDKN2A, MTAP, PTEN, RB1, NF1, TSC1) creating testable SL treatment hypotheses for a majority of patients with this malignancy. The gene discussed is CDKN2A; the disease is glioblastoma.